3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia, Myeloid, Chronic-Phase
4
Burkitt Lymphoma
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Leukemia
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Substance Withdrawal Syndrome
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Multiple Myeloma
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Glioma
1
Frailty
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Interventions
nilotinib
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Substance Withdrawal Syndrome
×
Dasatinib
×
Clear all
NCT04147533
2024-11-26
HALF
Masaryk University
Phase 2
Active not recruiting
150 enrolled